Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms CMD 011, CMD-011, CMD011 |
Target |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), T lymphocytes stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Hepatocellular Carcinoma | Phase 2 | CN | 08 Dec 2023 |